

Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry

By: [Piaserico, S](#) (Piaserico, Stefano)^[1]; [Cazzaniga, S](#) (Cazzaniga, Simone)^[2]; [Chimenti, S](#) (Chimenti, Sergio)^[3]; [Giannetti, A](#) (Giannetti, Alberto)^[4]; [Maccarone, M](#) (Maccarone, Mara)^[5]; [Picardo, M](#) (Picardo, Mauro)^[6]; [Peserico, A](#) (Peserico, Andrea)^[1]; [Naldi, L](#) (Naldi, Luigi)^[2]

Group Author(s): [Psocare Study Grp](#)

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Volume: 70

Issue: 2

Pages: 257-+

Article Number: UNSP 262.e1

DOI: 10.1016/j.jaad.2013.10.019

Published: FEB 2014

[View Journal Information](#)

4.449 **4.523**
2014 5 year

JCR® Category	Rank in Category	Quartile in Category
DERMATOLOGY	4 of 62	Q1

Abstract

Background: Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event.

Objective: We sought to assess the variables predicting the efficacy of the second TNF-alfa inhibitor in patients discontinuing the first TNF-alfa inhibitor.

Methods: Data from all 5423 consecutive patients starting TNF-alfa inhibitor therapy for psoriasis between September 2005 and September 2010 who were included in the Italian Psocare registry were analyzed.

Results: In 105 patients who switched to a second TNF-alfa inhibitor who had complete follow-up data, 75% improvement in the Psoriasis Area Severity Index score (PASI 75) was reached by 29% after 16 weeks and by 45.6% after 24 weeks. Patients who switched because of secondary loss of efficacy (loss of initial PASI 75 response) or adverse events/intolerance were more likely to reach PASI 75 than those who switched as a result of primary inefficacy (PASI 75 never achieved) (hazard ratio 2.7, 95% confidence interval 1.3-5.5 vs hazard ratio 2.0, 95% confidence interval 1.0-3.9 and 1, respectively).

Limitations: There was a small number of patients with complete follow-up data.

Conclusion: PASI 75 response in patients who switched from one antie-TNF-alfa agent to another was significantly reduced in patients who showed primary inefficacy of the first antie-TNF-alfa.